HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure

Bruce A. Buchholz, Esther Fultz, Kurt W. Haack, John S. Vogel, S. Douglas Gilman, Shirley J. Gee, Bruce D. Hammock, Xiaoying Hui, Ronald C. Wester, Howard I. Maibach

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Metabolites of atrazine were measured in human urine after dermal exposure using HPLC to separate and identify metabolites and accelerator mass spectrometry (AMS) to quantify them. Ring-labeled [14C]atrazine was applied for 24 h with a dermal patch to human volunteers at low (0.167 mg, 6.45 μCi) and high (1.98 mg, 24.7 μCi) doses. Urine was collected for 7 days. The urine was centrifuged to remove solids, and the supernatant was measured by liquid scintillation counting prior to injection on the HPLC to ensure that <0.17 Bq (4.5 pCi) was injected on the column. A reversed-phase gradient of 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile became less polar with increasing time and separated the parent compound and major atrazine metabolites over 31 min on an octadecylsilane column. Peaks were identified by coelution with known standards. Elution fractions were collected in 1-min increments; half of each fraction was analyzed by AMS to obtain limits of quantitation of 14 amol. Mercapturate metabolites of atrazine and dealkylated atrazine dominated the early metabolic time points, accounting for ~90% of the 14C in the urine. No parent compound was detected. The excreted atrazine metabolites became more polar with increasing time, and an unidentified polar metabolite that was present in all samples became as prevalent as any of the known ring metabolites several days after the dose was delivered. Knowledge of metabolite dynamics is crucial to developing useful assays for monitoring atrazine exposure in agricultural workers.

Original languageEnglish (US)
Pages (from-to)3519-3525
Number of pages7
JournalAnalytical Chemistry
Volume71
Issue number16
DOIs
StatePublished - Aug 15 1999

Fingerprint

Atrazine
Metabolites
Particle accelerators
Acetic Acid
Mass spectrometry
Scintillation
Assays
Water
Monitoring
Liquids

ASJC Scopus subject areas

  • Analytical Chemistry

Cite this

Buchholz, B. A., Fultz, E., Haack, K. W., Vogel, J. S., Gilman, S. D., Gee, S. J., ... Maibach, H. I. (1999). HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. Analytical Chemistry, 71(16), 3519-3525. https://doi.org/10.1021/ac990152g

HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. / Buchholz, Bruce A.; Fultz, Esther; Haack, Kurt W.; Vogel, John S.; Gilman, S. Douglas; Gee, Shirley J.; Hammock, Bruce D.; Hui, Xiaoying; Wester, Ronald C.; Maibach, Howard I.

In: Analytical Chemistry, Vol. 71, No. 16, 15.08.1999, p. 3519-3525.

Research output: Contribution to journalArticle

Buchholz, BA, Fultz, E, Haack, KW, Vogel, JS, Gilman, SD, Gee, SJ, Hammock, BD, Hui, X, Wester, RC & Maibach, HI 1999, 'HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure', Analytical Chemistry, vol. 71, no. 16, pp. 3519-3525. https://doi.org/10.1021/ac990152g
Buchholz BA, Fultz E, Haack KW, Vogel JS, Gilman SD, Gee SJ et al. HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. Analytical Chemistry. 1999 Aug 15;71(16):3519-3525. https://doi.org/10.1021/ac990152g
Buchholz, Bruce A. ; Fultz, Esther ; Haack, Kurt W. ; Vogel, John S. ; Gilman, S. Douglas ; Gee, Shirley J. ; Hammock, Bruce D. ; Hui, Xiaoying ; Wester, Ronald C. ; Maibach, Howard I. / HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. In: Analytical Chemistry. 1999 ; Vol. 71, No. 16. pp. 3519-3525.
@article{f5075cef55b1437290415801aaac1f86,
title = "HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure",
abstract = "Metabolites of atrazine were measured in human urine after dermal exposure using HPLC to separate and identify metabolites and accelerator mass spectrometry (AMS) to quantify them. Ring-labeled [14C]atrazine was applied for 24 h with a dermal patch to human volunteers at low (0.167 mg, 6.45 μCi) and high (1.98 mg, 24.7 μCi) doses. Urine was collected for 7 days. The urine was centrifuged to remove solids, and the supernatant was measured by liquid scintillation counting prior to injection on the HPLC to ensure that <0.17 Bq (4.5 pCi) was injected on the column. A reversed-phase gradient of 0.1{\%} acetic acid in water and 0.1{\%} acetic acid in acetonitrile became less polar with increasing time and separated the parent compound and major atrazine metabolites over 31 min on an octadecylsilane column. Peaks were identified by coelution with known standards. Elution fractions were collected in 1-min increments; half of each fraction was analyzed by AMS to obtain limits of quantitation of 14 amol. Mercapturate metabolites of atrazine and dealkylated atrazine dominated the early metabolic time points, accounting for ~90{\%} of the 14C in the urine. No parent compound was detected. The excreted atrazine metabolites became more polar with increasing time, and an unidentified polar metabolite that was present in all samples became as prevalent as any of the known ring metabolites several days after the dose was delivered. Knowledge of metabolite dynamics is crucial to developing useful assays for monitoring atrazine exposure in agricultural workers.",
author = "Buchholz, {Bruce A.} and Esther Fultz and Haack, {Kurt W.} and Vogel, {John S.} and Gilman, {S. Douglas} and Gee, {Shirley J.} and Hammock, {Bruce D.} and Xiaoying Hui and Wester, {Ronald C.} and Maibach, {Howard I.}",
year = "1999",
month = "8",
day = "15",
doi = "10.1021/ac990152g",
language = "English (US)",
volume = "71",
pages = "3519--3525",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure

AU - Buchholz, Bruce A.

AU - Fultz, Esther

AU - Haack, Kurt W.

AU - Vogel, John S.

AU - Gilman, S. Douglas

AU - Gee, Shirley J.

AU - Hammock, Bruce D.

AU - Hui, Xiaoying

AU - Wester, Ronald C.

AU - Maibach, Howard I.

PY - 1999/8/15

Y1 - 1999/8/15

N2 - Metabolites of atrazine were measured in human urine after dermal exposure using HPLC to separate and identify metabolites and accelerator mass spectrometry (AMS) to quantify them. Ring-labeled [14C]atrazine was applied for 24 h with a dermal patch to human volunteers at low (0.167 mg, 6.45 μCi) and high (1.98 mg, 24.7 μCi) doses. Urine was collected for 7 days. The urine was centrifuged to remove solids, and the supernatant was measured by liquid scintillation counting prior to injection on the HPLC to ensure that <0.17 Bq (4.5 pCi) was injected on the column. A reversed-phase gradient of 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile became less polar with increasing time and separated the parent compound and major atrazine metabolites over 31 min on an octadecylsilane column. Peaks were identified by coelution with known standards. Elution fractions were collected in 1-min increments; half of each fraction was analyzed by AMS to obtain limits of quantitation of 14 amol. Mercapturate metabolites of atrazine and dealkylated atrazine dominated the early metabolic time points, accounting for ~90% of the 14C in the urine. No parent compound was detected. The excreted atrazine metabolites became more polar with increasing time, and an unidentified polar metabolite that was present in all samples became as prevalent as any of the known ring metabolites several days after the dose was delivered. Knowledge of metabolite dynamics is crucial to developing useful assays for monitoring atrazine exposure in agricultural workers.

AB - Metabolites of atrazine were measured in human urine after dermal exposure using HPLC to separate and identify metabolites and accelerator mass spectrometry (AMS) to quantify them. Ring-labeled [14C]atrazine was applied for 24 h with a dermal patch to human volunteers at low (0.167 mg, 6.45 μCi) and high (1.98 mg, 24.7 μCi) doses. Urine was collected for 7 days. The urine was centrifuged to remove solids, and the supernatant was measured by liquid scintillation counting prior to injection on the HPLC to ensure that <0.17 Bq (4.5 pCi) was injected on the column. A reversed-phase gradient of 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile became less polar with increasing time and separated the parent compound and major atrazine metabolites over 31 min on an octadecylsilane column. Peaks were identified by coelution with known standards. Elution fractions were collected in 1-min increments; half of each fraction was analyzed by AMS to obtain limits of quantitation of 14 amol. Mercapturate metabolites of atrazine and dealkylated atrazine dominated the early metabolic time points, accounting for ~90% of the 14C in the urine. No parent compound was detected. The excreted atrazine metabolites became more polar with increasing time, and an unidentified polar metabolite that was present in all samples became as prevalent as any of the known ring metabolites several days after the dose was delivered. Knowledge of metabolite dynamics is crucial to developing useful assays for monitoring atrazine exposure in agricultural workers.

UR - http://www.scopus.com/inward/record.url?scp=0033566776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033566776&partnerID=8YFLogxK

U2 - 10.1021/ac990152g

DO - 10.1021/ac990152g

M3 - Article

C2 - 10464479

AN - SCOPUS:0033566776

VL - 71

SP - 3519

EP - 3525

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 16

ER -